Signature Diagnostics AG announced that on June 30 2010, company CEO, Andre Rosenthal, opened the scientific session of the European Society for Medical Oncology (ESMO) Conference: 12th World Congress on Gastrointestinal Cancer, in Barcelona, Spain, by presenting the positive results of its colorectal cancer screening test.
Detector C, an in-vitro diagnostic blood-based screening product for the early detection of colorectal cancer, has been shown to detect 90% of all colorectal cancers as well as a substantial proportion of precancerous lesions known as high-grade adenomas. Using Affymetrix technology to evaluate the expression of 202 genes that are active in response to tumor formation and growth, the test has shown a sensitivity of 90 percent for all four cancer stages (including early stages), and a specificity of 88 percent.
André Rosenthal, founder and CEO of Signature Diagnostics, cited the test’s significance in fulfilling a large unmet clinical need: "Detector C is the safest and most accurate blood -based screening test available, making it particularly well suited for population screening. It has the potential to provide an early warning to hundreds of thousands of individuals with early stage colorectal cancer, enabling them to begin treatment while their disease is still curable."
Signature Diagnostics plans to launch Detector C by the end of this year.
Source: Signature Diagnostics
